PatientsVille.com Logo


CABLE Medical Research Studies

Up-to-date List of CABLE Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest CABLE Medical Research Studies

Rank Status Study
1 Recruiting To Identify HLA-A1101-restricted Peptide Epitopes Derived From Novel Oncoantigens (URLC10, KIF20A, and CDCA1) Applicable for Cancer Vaccine in Singapore
Condition: Anonymous Donors at Blood Donation Center (NUH)
Outcome Measure: To identify HLA-A1101-restricted peptide epitopes derived from novel Oncoantigens (URLC10, KIF20A, and CDCA1) Applicable for Cancer Vaccine in Singapore.
2 Recruiting Erlotinib as Neoadjuvant Treatment in Patients With Stage ⅢA N2 NSCLC With Activating EGFR Mutation.
Condition: Non Small Cell Lung Cancer
Intervention: Drug: erlotinib
Outcome Measures: radical resection rate;   Pathological Complete Remission
3 Recruiting Observational Study to Assess the Incidence Rate of the Major Adverse Cardiovascular Events (MACE) and Safety of Fenofibrate (Lipilfen Capsule)
Condition: Metabolic Syndrome
Intervention: Other: Not Applicable-observational study
Outcome Measures: The incidence rate of the major adverse cardiovascular events (MACE);   The incidence rate of the major adverse cardiac and cerebrovascular event (MACCE)
4 Recruiting Kidney Cancer DNA Registry
Condition: Renal Cancer
Interventions: Other: salvia for germline DNA;   Behavioral: the Kidney Cancer Questionnaire;   Behavioral: Family History Questionnaire (when Applicable)
Outcome Measure: establish a kidney cancer registry
5 Recruiting Borderline Pancreas Study: FOLFIRINOX +SBRT
Condition: Resectable Pancreatic Cancer
Interventions: Other: Chemotherapy(FOLFIRINOX) + SBRT prior to surgery if Applicable;   Drug: -Oxaliplatin 85 mg/m2 IV on Day 1;   Drug: -Irinotecan 180 mg/m2 IV on Day 1;   Drug: -5-FU (Fluorouracil) 2,400 mg/m2 IV over 46-48 hours
Outcome Measures: Rate of downstaging to resectability in patients with borderline resectable pancreatic cancer receiving FOLFIRINOX and SBRT as preoperative therapy.;   Survival status (disease-free-survival vs. overall survival) time to recurrence and site of recurrence in patients with borderline resectable pancreatic cancer receiving preoperative FOLFIRINOX followed by SBRT
6 Recruiting Exploring Hypertonia in Children With Cerebral Palsy
Condition: Cerebral Palsy.
Intervention: Other: No intervention Applicable
Outcome Measures: Hypertonia Assessment Tool-Discriminate (HAT-D);   Barry-Albright Dystonia scale;   Modified Ashworth Scale
7 Recruiting Coughing in Brainstem Patients
Condition: Stroke
Intervention: Other: Not Applicable (observational study with no active intervention)
Outcome Measures: Diaphragm excursion;   Maximal inspiratory pressure;   Peak cough flow force during voluntary coughing
8 Recruiting Study of Biomarker Profiles in Asia Pacific erb2+/HER2 Breast Cancer Patients Treated With Lapatinib
Condition: Neoplasms, Metastasis
Intervention: Other: This study is non-interventional study, so this section is not Applicable.
Outcome Measures: Progression free survival;   Response rate;   Overall survival
9 Unknown  The Effect of OMT on Patients With COPD: Correlating Pulmonary Function Tests With Biochemical Alterations
Condition: Chronic Obstructive Pulmonary Disease
Interventions: Procedure: Osteopathic Manipulative Treatment (OMT);   Other: sham omt
Outcome Measures: Change from baseline in spirometry at 6 weeks and 12 weeks;   Change from baseline in P100 at 6 weeks and 12 weeks;   Change from baseline in MIP (maximum inspiratory pressure) and MEP (maximum expiratory pressure)at 6 weeks and 12 weeks.;   Change from baseline in inspiratory capacity at 6 weeks and 12 weeks.;   Change from baseline in exercise tolerance at 6 weeks and 12 weeks.;   Change from baseline in dyspnea (shortness of breath) at 6 weeks and 12 weeks.;   Change from baseline in quality of life at 6 weeks and 12 weeks.;   Change from baseline in profiling of the plasma metabolome at 6 weeks and 12 weeks.;   Change from baseline in profiling of plasma proteins at 6weeks and 12 weeks.
10 Recruiting Safety and Efficacy of a New Ophthalmic Formulation of Bimatoprost in Patients With Open Angle Glaucoma and Ocular Hypertension
Conditions: Open-Angle Glaucoma;   Ocular Hypertension
Interventions: Drug: bimatoprost ophthalmic formulation A;   Drug: bimatoprost ophthalmic formulation B;   Drug: bimatoprost ophthalmic formulation C;   Drug: bimatoprost ophthalmic formulation D;   Drug: bimatoprost ophthalmic formulation E;   Drug: bimatoprost ophthalmic formulation F;   Drug: Sham;   Drug: timolol 0.5%;   Drug: bimatoprost ophthalmic solution 0.03%;   Drug: latanoprost 0.005%;   Drug: timolol vehicle (placebo)
Outcome Measures: Stage 1: Change from Baseline in Intraocular Pressure (IOP);   Stage 2: Change from Baseline in IOP;   Stage 2: IOP;   Time to Escape Treatment;   Time to Second Injection
11 Recruiting A Study Evaluating the Efficacy and Safety of Botulinum Toxin Type A and Solifenacin in Patients With Overactive Bladder and Urinary Incontinence
Conditions: Overactive Bladder;   Urinary Incontinence
Interventions: Biological: botulinum toxin type A;   Drug: solifenacin;   Drug: placebo (normal saline);   Drug: solifenacin placebo
Outcome Measures: Number of Episodes of Urinary Incontinence;   Percentage of participants who are 100% incontinence-free/dry;   Percentage of participants with positive response on the single-item Treatment Benefit Scale;   Number of micturition episodes;   Number of Nocturia Episodes;   King's Health Questionnaire Role and Social Limitation Domain Scores
12 Recruiting Safety and Effectiveness of Regorafenib
Condition: Neoplasms
Intervention: Drug: Stivarga (Regorafenib, BAY73-4506)
Outcome Measures: Incidence of all treatment-emergent adverse events (TEAE) - Patients will be monitored for TEAE using the NCI-CTCAE Version 4.3;   Overall Survival (OS), OS is defined as the time interval from the start of regorafenib therapy to death, due to any cause.;   Progression free survival (PFS) is defined as the time interval measured from the day of start with regorafenib treatment to (radiological or clinical) progression or death, whichever comes first.;   Disease control rate (DCR) - DCR is defined as percentage of patients, whose best response was not progressive disease (i.e. CR, PR or SD). Stable disease must be at least 6 weeks in duration.;   Quality of Life - HRQoL using PRO questionnaire EQ-5D (8) in Applicable countries;   Healthcare resource utilization
13 Not yet recruiting Biomarker Correlates of Hypoxia in Metastatic Melanoma
Conditions: Melanoma;   Skin Cancer
Interventions: Drug: Pimonidazole hydrochloride (Hypoxyprobe™-1);   Drug: Optional 18F-FMISO PET scan (18F-fluoromisonidazole);   Procedure: Surgical Resection of Melanoma Metastases
Outcome Measure: Percentage of Positive Biomarker Staining by Applicable Area
14 Recruiting Development and Validation Phase of Diffusion Tensor Imaging and Arterial Spin Labelling at 3 Tesla Using a Long-term Effort Model Applicable to Skeletal Muscle Characterization.
Conditions: Marathoners.;   Men Between 25 and 50 Years Old.
Intervention: Device: Magnetic Resonance Imaging (MRI)
Outcome Measures: Fractional Anisotropy (FA) measure;   Apparent Diffusion Coefficient (ADC) value
15 Recruiting Botulinum Toxin Type A (BOTOX®) Treatment of Masseter Muscle Hypertrophy
Condition: Masticatory Muscles, Hypertrophy of
Interventions: Biological: botulinum toxin Type A;   Drug: Normal saline
Outcome Measures: Lower Facial Volume Calculated by Digital Imaging;   Investigator's Assessment of Masseter Muscle Hypertrophy (MMH) using a 5-Point Scale
16 Unknown  Astaxanthin Supplementation in Cyclists
Condition: Athletic Performance
Interventions: Dietary Supplement: astaxanthin;   Dietary Supplement: placebo
Outcome Measures: time trial performance;   substrate use
17 Recruiting Validation of a New Method of Limb Volumetry
Conditions: Edema;   Chronic Venous Insufficiency;   Lymphedema
Outcome Measure: Difference between limb volume measured
18 Recruiting Phase 2 Trial of Blinatumomab in Philadelphia Positive/BCR-ABL Positive Acute Lymphoblastic Leukemia
Condition: Relapsed/Refractory Philadelphia Positive B-precursor Acute Lymphoblastic Leukemia
Intervention: Drug: Blinatumomab
Outcome Measures: Number of Participants with CR/CRh* within 2 cycles of treatment with blinatumomab;   Number of Participants with MRD remission within 2 cycles of treatment with blinatumomab;   Duration of CR or CRh*;   Number of Participants with CR within 2 cycles of treatment with blinatumomab;   Number of Participants with CRh* rate within 2 cycles of treatment with blinatumomab;   Number of Participants with CR+CRh*+ Complete Response incomplete (CRi) rate within 2 cycles of treatment with blinatumomab;   Overall survival;   Number of Participants undergoing Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT) and 100-day mortality after alloHSCT;   Number of Participants with Adverse Events as a Measure of Safety and Tolerability and number of participants withIncidence of adverse events and antibody formation;   Serum concentration of blinatumomab
19 Recruiting Biomarkers in Tissue Samples From Patients With High-Risk Wilms Tumor
Conditions: Clear Cell Sarcoma of the Kidney;   Recurrent Wilms Tumor and Other Childhood Kidney Tumors;   Rhabdoid Tumor of the Kidney;   Stage I Wilms Tumor;   Stage II Wilms Tumor;   Stage III Wilms Tumor;   Stage IV Wilms Tumor;   Stage V Wilms Tumor
Interventions: Genetic: DNA methylation analysis;   Genetic: gene expression analysis;   Genetic: microarray analysis;   Genetic: reverse transcriptase-polymerase chain reaction;   Other: diagnostic laboratory biomarker analysis
Outcome Measures: Genomic gains and losses in high-risk Wilms tumor;   Transcription patterns involved in the pathogenesis of Wilms tumor;   Genetic mutations involved in the pathogenesis of Wilms tumor
20 Unknown  Laboratory Study of Lymphoblasts in Young Patients With High-Risk Acute Lymphoblastic Leukemia
Condition: Leukemia
Interventions: Genetic: loss of heterozygosity analysis;   Genetic: microarray analysis;   Genetic: polymorphism analysis;   Genetic: tumor replication error analysis
Outcome Measures: Identification of regions of copy number abnormalities (CNA) and uniparental disomy in leukemic lymphoblasts using Affymetrix GeneChip Mapping 500K array sets;   Identification of regions of CNA and loss-of-heterozygosity using Affymetrix SNP 6.0 microarrays. (Expansion project);   Gene expression profiles for leukemic lymphoblasts using Affymetrix U133 Plus 2.0 arrays;   Global expression of microRNAs in leukemic lymphoblasts using microRNA gene chips;   Epigenomic profiles using the HpaII tiny fragment Enrichment by Ligation-mediated PCR (HELP) assay. (Expansion project);   Prioritization of candidate genes and genomic regions for resequencing using array-generated gene expression data and data for CNAs;   Identification of genes that are consistently mutated in leukemic lymphoblasts using high-throughput focused gene resequencing

These studies may lead to new treatments and are adding insight into CABLE etiology and treatment.

A major focus of CABLE research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.

Discuss CABLE